Reduction in systemic glucocorticoid utilization among COPD patients with type 2 inflammation treated with biologics
Abstract Background Systemic glucocorticoids are associated with significant side effects, however, are essential in the treatment of acute exacerbations of chronic obstructive pulmonary disease (COPD). Biologic therapies in COPD with type 2 (T2) inflammation have shown benefit in reducing exacerbat...
Saved in:
| Main Authors: | Truong-An A. Ho, Stephen Dachert, Anugya Mittal, Gerard J. Criner |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-07-01
|
| Series: | BMC Pulmonary Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12890-025-03809-4 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Variability of blood eosinophil count and prognosis of COPD exacerbations
by: Sandra Martínez-Gestoso, et al.
Published: (2021-01-01) -
Utility of neutrophil to lymphocyte ratio in the prediction of inflammation and COPD mortality
by: Sanja Dimic-Janjic, et al.
Published: (2025-05-01) -
Diagnosis and approach to glucocorticoid-induced adrenal insufficiency and glucocorticoid withdrawal syndrome
by: Aleksandra Kiełczewska, et al.
Published: (2024-11-01) -
INHIBITION OF REDD1 EXPRESSION FOR THE REDUCTION OF GLUCOCORTICOID-INDUCED SIDE EFFECTS
by: E. S. Lylova, et al.
Published: (2020-12-01) -
FEATURES OF CYTOKINE-MEDIATED REGULATION OF FOCAL AND SYSTEMIC INFLAMMATION IN COPD
by: E. A. Surkova, et al.
Published: (2014-07-01)